Johnson & Johnson Innovative Medicine, Maynooth University, Science Foundation Ireland (SFI) Centre for Future Networks & Communications (CONNECT) and Mater Misericordiae University Hospital announced a new partnership today to introduce an innovative health app to support people living with rare disease, Pulmonary Arterial Hypertension. The bespoke app will enable better management of rare condition to improve health outcomes and quality of life.
Johnson & Johnson Innovative Medicine, Science Foundation Ireland (SFI) CONNECT Centre for Future Networks & Communications, Maynooth University and Mater Misericordiae University Hospital partner to deliver bespoke app enabling better management of rare condition – Pulmonary Arterial Hypertension
Johnson & Johnson Innovative Medicine, SFI CONNECT Centre for Future Networks & Communications (CONNECT), Maynooth University and Mater Misericordiae University Hospital announced a new partnership today to introduce an innovative health app. This application has been specifically developed using award-winning technology deployed by many UK-based hospitals and is designed to provide essential tools and information for patients living with pulmonary arterial hypertension (PAH), supporting improved health outcomes and quality of life right from their homes. The app also enables medical teams to educate patients about their condition and encourages proactive health management.
For verified healthcare professionals
Log in or register for free to read this article. HPN is for healthcare professionals, so new accounts are verified by our team.
